Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 6/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | CYP46A1 | Q9Y6A2 | 1/20 | 0.42 |
| ▸ | LTA4H | P09960 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8109453 | 0.83 | TSHR (0.45) | TSHRALDH1A1SMN1; SMN2CYP3A4CYP2C19 | |
| SCHEMBL4536069 | 0.80 | ALDH1A1 (0.56) | TSHRALDH1A1CYP3A4CYP2C19GAA | |
| SCHEMBL2842489 | 0.80 | TSHR (0.52) | TSHRALDH1A1CYP3A4CYP2C19LMNA | |
| SCHEMBL4536524 | 0.80 | TSHR (0.56) | TSHRALDH1A1SMN1; SMN2CYP3A4CYP2C19 | |
| SCHEMBL2839009 | 0.77 | SLC6A2 (0.54) | TSHRKMT2AMEN1 | |
| SCHEMBL27798401 | 0.77 | ALDH1A1 (0.66) | TSHRALDH1A1CYP3A4CYP2C19LMNA | |
| SCHEMBL2846505 | 0.77 | GAA (0.68) | TSHRALDH1A1SMN1; SMN2CYP3A4CYP2C19 | |
| SCHEMBL28709245 | 0.77 | ALDH1A1 (0.56) | TSHRALDH1A1SMN1; SMN2LMNAKMT2A | |
| SCHEMBL2838023 | 0.76 | HRH1 (0.51) | TSHRALDH1A1CYP3A4CYP2C19LMNA | |
| SCHEMBL28785742 | 0.75 | TSHR (0.48) | TSHRALDH1A1SMN1; SMN2CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096565-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2015-08-04 | — | — | US | disclosed |
| US-9096565-B2 | Inhibitors of histone deacetylase | METHYLGENE INC. (CA) | 2015-08-04 | — | — | US | disclosed |
| US-20090181943-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2009-07-16 | — | — | US | disclosed |
| US-20090181943-A1 | Inhibitors of Histone Deacetylase | METHYLGENE INC. (CA) | 2009-07-16 | — | — | US | disclosed |
| WO-2008122115-A1 | INHIBITORS OF HISTONE DEACETYLASE | METHYLGENE INC. (CA) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181943-A1 | Inhibitors of Histone Deacetylase | HDAC1, HDAC11, HDAC3 | TSHR 3972/4885ALDH1A1 532/4885SMN1; SMN2 3638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.